CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

Inclusion Criteria: * Relapsed or refractory CD19+ B-cell lymphoma or leukemia. * Measurable disease. * Performance status ECOG 0-2. * \>18 years old. * Fertile females/males must consent to use contraceptives during participation of the trial. * Signed informed consent. Exclusion Criteria: * Any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures. * Patients with primary CNS lymphoma. * Known human immunodeficiency virus (HIV) infection. * Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection). * Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the patient. * Treatment with an investigational product within 30 days prior to enrollment, or at least 5 half lives of that drug, which is longest. * Patients that do not consent to that tissue and blood samples are stored in a biobank. * Pregnancy